TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11301561
Drug: (R)-albuterol 5
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (R)-albuterol 5 mg
Study: 11301561
Drug: (S)-albuterol 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: (S)-albuterol 1.25 mg
Study: 11301561
Drug: (R)-albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (R)-albuterol
Study: 11301561
Drug: (RS)-albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (RS)-albuterol
Study: 11301561
Drug: (R)-albuterol and
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (R)-albuterol and (RS)-albuterol
Study: 11301561
Drug: (S)-albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (S)-albuterol
Study: 8148281
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CyA) 5 mg/kg/day
Study: 8148281
Drug: Continuous reducing
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous reducing dose of CyA (1 mg/kg/day)
Study: 8148281
Drug: Intermittent fixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent fixed dose of CyA (5 mg/kg every fifth day)
Study: 3211287
Drug: oral scopolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral scopolamine 0.3 mg
Study: 3211287
Drug: oral scopolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral scopolamine 0.6 mg
Study: 3211287
Drug: oral scopolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral scopolamine 1.2 mg
Study: 3211287
Drug: oral methylscopolamine
Normalized name: methscopolamine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral methylscopolamine 0.6 mg
Study: 18261569
Drug: Single low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single low-dose anti-thymocyte globulin (ATG) prophylaxis (4-5 mg/kg)
Study: 18261569
Drug: Standard immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard immunosuppressive therapy (cyclosporine, mycophenolate mofetil or azathioprine, and prednisolone)
Study: 14743647
Drug: High-dose steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose steroids (30 mg/kg/d of methylprednisolone for three to five days with a six-week taper)
Study: 3279578
Drug: Low-dose steroids
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose steroids
Study: 14743647
Drug: Steroids (general
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids (general use)
Study: 14743647
Drug: Treatments studied
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatments studied in adults (applied to children with MS)
Study: 10817948
Drug: Linguagraph (used
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linguagraph (used for therapy and assessment)
Study: 6096349
Drug: Ampicillin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin (500 mg) plus sulbactam (500 mg)
Study: 6096349
Drug: Ampicillin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin (500 mg) plus metronidazole (1 g suppository)
Study: 6096349
Drug: Treatment groups
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment groups (A + B)
Study: 27269661
Drug: Fast-acting refrigerant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-acting refrigerant topical agent (applied for 5 seconds)
Study: 27269661
Drug: 20% benzocaine
Normalized name: BENZOCAINE 200 mg in 1 g DENTAL GEL [Ipana 20% Benzocaine Topical]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% benzocaine gel topical (applied for 2 minutes)
Study: 21890591
Drug: JNJ-37822681 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-37822681 at 5 mg
Study: 21890591
Drug: JNJ-37822681 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-37822681 at 10 mg
Study: 21890591
Drug: JNJ-37822681 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-37822681 at higher doses (15 mg and 20 mg)
Study: 21890591
Drug: JNJ-37822681 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-37822681 (various doses)
Study: 17386348
Drug: Enalapril treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril treatment for 2.5 years
Study: 11431653
Drug: 12-hour myoglobin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-hour myoglobin < or = 239 ng/mL
Study: 11431653
Drug: 12-hour troponin-I
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-hour troponin-I > 81.5 ng/mL
Study: 11431653
Drug: 12-hour CK-MB
Normalized name: MBS
DrugBank: Morpholinylmercaptobenzothiazole (DB14202)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-hour CK-MB > 191 ng/mL
Study: 11431653
Drug: 12-hour myoglobin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-hour myoglobin > 239 ng/mL
Study: 11431653
Drug: 12-hour troponin-I
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-hour troponin-I < or = 81.5 ng/mL
Study: 11431653
Drug: 12-hour CK-MB
Normalized name: MBS
DrugBank: Morpholinylmercaptobenzothiazole (DB14202)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-hour CK-MB < or = 191 ng/mL
Study: 9672343
Drug: Hyperphosphate enema
Normalized name: disodium dihydrogen hypophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperphosphate enema administered 1 and 2 h before the procedure, preceded by a 296 ml bottle of magnesium citrate taken p.o. the night before
Study: 7974313
Drug: Salmeterol xinafoate
Normalized name: Salmeterol Xinafoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol xinafoate 50 micrograms twice daily
Study: 2690316
Drug: SMS 201-995
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS 201-995 (200 micrograms, subcutaneously, 1 ml, three times within 16 hours)
Study: 2690316
Drug: Isotone saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotone saline (control, subcutaneously, 1 ml, three times within 16 hours)
Study: 25738850
Drug: ATX-101 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATX-101 (2 mg/cm2, total dose 100 mg)
Study: 21733283
Drug: D-serine (DSR)
Normalized name: D-Serine
DrugBank: D-Serine (DB03929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-serine (DSR) 30 mg/kg.d
Study: 15073698
Drug: Preoperative heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative heparin therapy (POHI group)
Study: 9589675
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH) therapy (approximately 0.22 IU/kg.week) for 24 months
Study: 7604796
Drug: Fluvastatin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin monotherapy (40 mg/day)
Study: 7604796
Drug: Fluvastatin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin monotherapy (30.2 mg/day)
Study: 7604796
Drug: Fluvastatin (39.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (39.3 mg/day) plus cholestyramine (10.3 mg/day)
Study: 7604796
Drug: Fluvastatin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin monotherapy (32.5 mg/day)
Study: 7604796
Drug: Fluvastatin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin monotherapy
Study: 2191507
Drug: Intravenous nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous nifedipine (0.8-1.0 mg)
Study: 506972
Drug: Continental type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continental type breakfast served with coffee (standardized against reference dose of 3 mg Fe from derrous ascorbate)
Study: 28164407
Drug: BUP‐NLX taper
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUP‐NLX taper
Study: 25510446
Drug: 70‐kVp and
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70‐kVp and CM 64 mL
Study: 25510446
Drug: 70‐kVp and
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70‐kVp and CM 40 mL
Study: 25510446
Drug: 120‐kVp and
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120‐kVp and CM 64 mL
Study: 25307707
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml ropivacaine 7.5 mg/ml (R group)
Study: 15191155
Drug: Budesonide 400
Normalized name: Budesonide 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 400 microg once daily
Study: 9718191
Drug: UV-B irradiation
Normalized name: Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UV-B irradiation at half the minimal erythemal dose of the lower back, three times per week during 12 weeks
Study: 9718191
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D3 400 IU/day during 12 weeks
Study: 7651075
Drug: Synthesized all‐trans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthesized all‐trans beta‐carotene (60 mg daily)
Study: 21942184
Drug: Medication (Tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Tramadol Hydrochloride Capsules 100 mg)
Study: 29191951
Drug: Active CPAP
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active CPAP therapy
Study: 10389123
Drug: Control 0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control 0.3% tobramycin solution
Study: 9049706
Drug: Iloprost treatment
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost treatment
Study: 1725068
Drug: 6 MU
Normalized name: Pancrelipase 16 mu
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 MU (= 10.4 mg) BM 06.022
Study: 6847852
Drug: Fructose, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose, 50 g as a 10% solution
Study: 6847852
Drug: Sucrose, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose, 50 g as a 10% solution
Study: 31959167
Drug: Budesonide/formoterol 160/4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol 160/4.5 μg
Study: 28830881
Drug: Allopurinol dose
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol dose escalation (DE)
Study: 30107437
Drug: Baseline SU
Normalized name: Sus scrofa skin
DrugBank: Sus scrofa skin (DB10606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline SU ⩾ 8 mg/dl
Study: 15222589
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of alcohol (0.34 g/kg women; 0.4 g/kg men)
Study: 9451581
Drug: Systemic injections
Normalized name: Vaginal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic injections of adrenergic antagonist L657,743
Study: 1839585
Drug: Ticlopidine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (250 mg b.i.d.)
Study: 25050591
Drug: Infliximab 3
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 3 mg/kg infused at Weeks 0, 2, 6, 14, and 22, with escalation to 5 or 7 mg/kg based on EULAR response at Weeks 14 and 22.
Study: 25050591
Drug: Infliximab 3
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 3 mg/kg with dose escalation based on EULAR response.
Study: 25050591
Drug: Infliximab treatment
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab treatment with dose escalation.
Study: 12654955
Drug: CR oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR oxycodone (10 mg tablet every 12 hours, max 60 mg every 12 hours)
Study: 12654955
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical tablet every 12 hours)
Study: 19092248
Drug: CR oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR oxycodone
Study: 1726003
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of lacidipine once daily (n = 220)
Study: 1726003
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of nifedipine SR twice daily (n = 215)
Study: 1726003
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of lacidipine once daily (n = 82)
Study: 1726003
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of nifedipine SR twice daily (n = 62)
Study: 1726003
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of atenolol once daily (n = 32)
Study: 1726003
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of atenolol once daily (n = 23)
Study: 6486846
Drug: Mild topical
Normalized name: silver protein mild topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild topical antimicrobial wet dressings (Sweitzer's 1:32 solution)
Study: 25128594
Drug: Topical loteprednol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical loteprednol etabonate and eyelid scrubs with warm compresses (Group I)
Study: 22669848
Drug: Intravitreal pegaptanib
Normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravitreal pegaptanib (Macugen® 0.3 mg = 0.02 mL) combined with conventional diode laser photocoagulation in group 1 (68 eyes of 34 infants)
Study: 22669848
Drug: Conventional laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional laser therapy combined with cryotherapy in group 2 (84 eyes of 42 infants)
Study: 16195124
Drug: Night-time milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Night-time milk containing 10-40 ng/l melatonin, consumed daily for 8 weeks.
Study: 12869401
Drug: Subjects randomized,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized, sequential order known to the reader
Study: 10887919
Drug: Propofol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2.5 mg/kg) and Alfentanil (10 microg/kg)
Study: 3318546
Drug: Thiopental (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (5 mg/kg)
Study: 10887919
Drug: Thiopental (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (5 mg/kg) and Vecuronium (0.1 mg/kg)
Study: 8629746
Drug: HBOC‐201 (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBOC‐201 (45 g)
Study: 7595029
Drug: Control solution
Normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control solution (Ringer's lactate)
Study: 3905222
Drug: Sodium diclofenac
Normalized name: Diclofenac Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium diclofenac 50 mg 3 times daily
Study: 3905222
Drug: Proglumethacin 150
Normalized name: proglumetacin
DrugBank: Proglumetacin (DB13527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proglumethacin 150 mg 3 times daily
Study: 29982939
Drug: L‐PRF used
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐PRF used in addition to another layer
Study: 26435033
Drug: Insulin initiation
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin initiation with glargine, with or without glulisine
Study: 24773163
Drug: Missing a
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Missing a dose of HIV medications
Study: 23134888
Drug: HSF-DHA diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSF-DHA diet (3.45 g DHA/d)
Study: 19195454
Drug: Darunavir/ritonavir (800/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/ritonavir (800/100 mg once daily)
Study: 19195454
Drug: Lopinavir/ritonavir (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (once or twice daily)
Study: 9805325
Drug: Young normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Young normal participants with concurrent memory load
Study: 7695306
Drug: 882C87 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: 882C87 200 mg
Study: 7695306
Drug: 882C87 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: 882C87 400 mg
Study: 7695306
Drug: 882C87 1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: 882C87 1600 mg
Study: 7695306
Drug: 882C87 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: 882C87 50 mg (elderly)
Study: 7695306
Drug: 882C87 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: 882C87 100 mg (elderly)
Study: 7695306
Drug: 882C87 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: 882C87 50 to 400 mg
Study: 351218
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment (adjusted dosage to achieve normoglycemia)
Study: 351218
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose of insulin
Study: 7039378
Drug: Ticarcillin (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticarcillin (one 6 g dose at the start of the operation)
Study: 7039378
Drug: Cephalothin (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalothin (three 2 g doses given at 4 hour intervals from the start of the operation)
Study: 18372395
Drug: Solabegron 50
Normalized name: Solabegron
DrugBank: Solabegron (DB06190)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solabegron 50 mg twice daily
Study: 18372395
Drug: Solabegron 200
Normalized name: Solabegron
DrugBank: Solabegron (DB06190)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solabegron 200 mg twice daily
Study: 12875702
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg rosiglitazone once daily plus sulphonylurea
Study: 12875702
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g metformin twice daily plus sulphonylurea
Study: 10563066
Drug: Cerivastatin 0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin 0.025 mg
Study: 10563066
Drug: Cerivastatin 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin 0.05 mg
Study: 10817086
Drug: Cerivastatin 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin 0.1 mg
Study: 10563066
Drug: Cerivastatin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin (all doses)
Study: 10563066
Drug: Cerivastatin 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin 0.1 mg and 0.2 mg
Study: 1957618
Drug: Milk cereal
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk cereal fortified with ferrous fumarate (7.5 mg/100 g)
Study: 1957618
Drug: Milk cereal
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk cereal fortified with ferric-pyrophosphate (7.5 mg/100 g)
Study: 10382188
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no nutritional supplement)
Study: 6359383
Drug: ampicillin plus
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ampicillin plus cloxacillin (2 g of each daily for 6 days)
Study: 6359383
Drug: ticarcillin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ticarcillin (5 g X 12, 8‐hourly)
Study: 6359383
Drug: carbenicillin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: carbenicillin (10 g X 12, 8‐hourly)
Study: 6359383
Drug: clindamycin (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: clindamycin (900 mg, 4 daily doses)
Study: 6359383
Drug: clindamycin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: clindamycin plus netilmicin (90 mg, 4 daily doses)
Study: 31206956
Drug: 0.2 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mL/kg 24% sucrose
Study: 31206956
Drug: 0.5 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL/kg 24% sucrose
Study: 29230663
Drug: PEG‐rhG‐CSF 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐rhG‐CSF 100 µg/kg
Study: 26796802
Drug: PEG‐rhG‐CSF 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐rhG‐CSF 6 mg
Study: 29230663
Drug: PEG‐rhG‐CSF 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐rhG‐CSF 100 µg/kg and 6 mg
Study: 25234339
Drug: 500 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/d of RRR‐α‐tocopherol
Study: 25234339
Drug: 500 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/d of mixed tocopherols
Study: 25234339
Drug: 500 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/d of vitamin C
Study: 25234339
Drug: 1000 mg/d
Normalized name: RibaTab 1000 MG/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/d of grape‐seed polyphenols
Study: 15023611
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vitamin C and polyphenols
Study: 22391079
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate nasal spray (FFNS), 110 μg, daily for 1 year
Study: 22391079
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (MFNS), 200 μg, daily for 1 year
Study: 18629723
Drug: Quest plus
Normalized name: Quest Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quest plus placebo patch
Study: 6166691
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (spontaneous decrease)
Study: 25543426
Drug: Fentanyl citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl citrate injection at auricular points (0.25 mL at each point)
Study: 25543426
Drug: Subcutaneous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous fentanyl citrate injection in the deltoid muscle (1 mL)
Study: 25543426
Drug: Subcutaneous sodium
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous sodium chloride injection in the deltoid muscle (1 mL)
Study: 22351892
Drug: ω‐3 group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3 group (500‐mg daily fish oil supplement and canola-based margarines and cooking oil)
Study: 22351892
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (500‐mg daily sunflower oil supplement and ω‐6 fatty acid-rich margarines and cooking oil)
Study: 12837811
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 every 3 weeks (DC)
Study: 12837811
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 and carboplatin area under the curve of 6 mg/mL * min every 3 weeks (DCb)